In a clinical study of 188 people with previously treated HER2+ advanced stomach cancer, ENHERTU helped people live longer than with chemotherapy.* Among people in the trial, half of the people taking ENHERTU were alive at 12.5 months. For people taking chemotherapy, half of the people were alive at 8.4 months.† This was about 4 months longer with ENHERTU.
In the same clinical study, tumors shrank in more people treated with ENHERTU than with chemotherapy*‡:
- 40.5% (51 of 126) of people saw a confirmed response with ENHERTU and 11.3% (7 of 62) did with chemotherapy‡§
- 7.9% (10 of 126) of people taking ENHERTU achieved a complete response, meaning their tumor could not be seen on imaging tests. This does not always mean the cancer has been cured. No one taking chemotherapy (0 of 62) had a complete response
- 32.5% (41 of 126) of people taking ENHERTU achieved a partial response, which means the tumor shrank by at least 30%. 11.3% (7 of 62) of those taking chemotherapy had a partial response
- 84% (106 of 126) of people taking ENHERTU saw their tumors shrink, stop growing, or the growth of their tumors slowed, and 61% (38 of 62) of people saw this while receiving chemotherapy||
Learn more about the clinical study results
*Chemotherapy used in the clinical study was the doctor’s choice between 2 commonly used chemotherapies (irinotecan or paclitaxel).
†63 of 126 people taking ENHERTU were still alive after 12.5 months vs 23 out of 62 people taking chemotherapy.
‡The number of people who had their tumors shrink is called the overall response rate (or ORR). ORR was achieved by 51 out of 126 people with ENHERTU compared to 7 out of 62 people with chemotherapy.
§The response was observed by the treating doctor and then agreed upon by a review panel. A second scan 4 or more weeks after the first was used to confirm the results.
||The 84% shown is the disease control rate, which is the sum of the ORR and stable disease rate. Stable disease means that the tumor did not increase in size by more than 20% nor decrease in size by more than 30%.
What is ENHERTU?
ENHERTU (en-HER-too) is a prescription medicine used to treat adults who have stomach cancer called gastric or gastroesophageal junction (GEJ) adenocarcinoma that is HER2-positive and has spread to areas near your stomach (locally advanced) or that has spread to other parts of your body (metastatic), and who have received a prior trastuzumab-based regimen.
It is not known if ENHERTU is safe and effective in children.
What is the most important information I should know about ENHERTU?
ENHERTU can cause serious side effects, including:
- Lung problems that may be severe, life-threatening or that may lead to death. If you develop lung problems your healthcare provider may treat you with corticosteroid medicines. Tell your healthcare provider right away if you get any of the following signs and symptoms:
Please see full Prescribing Information, including Boxed WARNINGS, and Medication Guide.
Financial support